Nguyen Ai-Lan, Gresle Melissa, Marshall Tessa, Butzkueven Helmut, Field Judith
Melbourne Brain Centre and Department of Medicine at the Royal Melbourne Hospital, University of Melbourne, Parkville, Vic., Australia.
Multiple Sclerosis Division, The Florey Institute of Neuroscience and Mental Health, Parkville, Vic., Australia.
Br J Pharmacol. 2017 Jul;174(13):1895-1907. doi: 10.1111/bph.13780. Epub 2017 Apr 26.
Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS, and one of the most common causes of disability in young adults. Over the last decade, new disease-modifying therapies have emerged, including monoclonal antibodies (mAbs) that provide highly targeted therapies with greater efficacy than platform therapies. In particular, monoclonal antibodies directed against CD20-positive B cells have shown remarkable results in recent clinical trials and renewed interest in the mechanism of B cell-depleting therapies to ameliorate relapse activity and progression in MS. Here, we review the mechanisms of action and clinical evidence of approved and emerging mAbs, with a focus on B cell-targeted therapies.
多发性硬化症（MS）是一种中枢神经系统的慢性炎症性疾病，也是年轻成年人残疾的最常见原因之一。在过去十年中，出现了新的疾病修正疗法，包括单克隆抗体（mAb），这些抗体提供了高度靶向的疗法，其疗效优于传统疗法。特别是，针对CD20阳性B细胞的单克隆抗体在最近的临床试验中显示出显著效果，并重新引发了人们对B细胞清除疗法改善MS复发活动和疾病进展机制的兴趣。在这里，我们回顾了已批准和新出现的单克隆抗体的作用机制和临床证据，重点是B细胞靶向疗法。
